Log In
Print this Print this

Anti-HER2-ADC (SYD985)

  Manage Alerts
Collapse Summary General Information
Company Synthon B.V.
DescriptionAntibody-drug conjugate (ADC) consisting of trastuzumab, a humanized mAb against HER2, conjugated to duocarmycin analogs, a class of DNA minor groove-binding agents, using SpaceLink technology
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionAntibody-drug conjugate; Epidermal growth factor (EGF) receptor 2 (HER2) (ErbB2) (neu) inhibitor
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat locally advanced or metastatic solid tumors
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today